While SGLT2, metformin, statins, and trimetazidine have received significant attention in the treatment of cardiovascular diseases because of their activation of AMPK (51–54), our findings suggest that BAIBA administration could be an alternative therapeutic approach to reduce metabolic stress and mitochondrial dysfunction in HF. The gene discussed is SLC5A2; the disease is hydrops fetalis.